TargetBeta
APOC3
apolipoprotein C3 · also Apo-CIII, ApoC-III, APOCIII, Apo-C3 · Apolipoproteins
3 programs in company-led studies act on APOC3, from 3 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| HRS-7249 | Jiangsu HengRui Medicine | phase 2 | 43 running | – | the company's pipeline |
| FXR0906 | Fosun Pharma | phase 2 | 22 running | – | the company's pipeline |
| CS-121rule | CorrectSequence Therapeutics | early phase 1 | 22 running | – | the studies' text |
Conditions their studies are in
- Hypertriglyceridemia, 2 programs
- Hyperlipidemias, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026CS-121 · CorrectSequence Therapeutics · early phase 1 · NCT07176923
- Jun 2027HRS-7249 · Jiangsu HengRui Medicine · phase 2 · NCT07308392
- Sep 24, 2027FXR0906 · Fosun Pharma · phase 2 · NCT07766759
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.